Clinical trial
A Randomized, Double-blind, Placebo-controlled Research Study Evaluating the Efficacy and Safety of Multi-dose Fecal Microbiota Transplantation (FMT) in Capsule Form as an Intervention to Slow Down the Rate of Biological Aging.
NCT07912164 is registered in ClinicalTrials.gov with Human Biome S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Research Study Evaluating the Efficacy and Safety of Multi-dose Fecal Microbiota Transplantation (FMT) in Capsule Form as an Intervention to Slow Down the Rate of Biological Aging.
- Lead sponsor
- Human Biome S.A.
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- December 31, 2027
- Enrollment
- 68 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
aging and cognitive health, aging, healthy, fecal microbiota transplantation (fmt), inflammaging, inflammation, longevity, metabolic syndrome
Arms
As registered; 2 arms.
-
MBiotix HBI Caps
MBiotix HBI Caps (FMT capsules) + Preparation antibiotics (Neomycin and Metronidazole) + Standard bowel cleansing (Macrogols). Participants receive targeted preparation antibiotics followed by bowel cleansing, and then a multi-dose regimen of fecal microbiota transplantation (FMT) capsules (MBiotix HBI Caps) in an initial induction phase and subsequent booster cycles.
-
Placebo
Placebo Capsules (matching MBiotix HBI Caps) + Antibiotics Placebo (matching two active antibiotics) + Standard bowel cleansing (Macrogols). Participants receive matching placebo treatments for both the preparation antibiotics and the oral capsules (MBiotix HBI placebo), along with the same standard bowel cleansing and multi-dose schedule (an initial induction phase and subsequent booster cycles).
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Percentage of Participants Achieving Clinical and Biological Response (Responder Rate)
The primary outcome is the proportion of participants categorized as "Responders" following multi-dose fecal microbiota transplantation (MBiotix HBI Caps) compared to placebo. A participant is classified as a Responder if they demonstrate objective physiological improvement from Baseline to Week 13 and/or Week 26, defined as meeting at least one of the following two pre-specified criteria:
* Epigenetic Deceleration: A reduction of at least 5% from baseline in the DunedinPACE biological pace-of-aging algorithm.
* Attenuation of Inflammaging: A reduction of at least 25% from baseline in at least one circulating systemic inflammatory marker from the predefined panel (provided the marker was significantly elevated at baseline per study inclusion criteria).Results will be reported as the percentage of participants in each treatment arm meeting this composite response definition.
Lead sponsor's other trials
Human Biome S.A., most recent start first.
Similar trials
Same condition (Metabolic Syndrome) and phase, most recent start first.
+1,164 more trials See the condition page